Applications

Vascular Access Catheters

SIZE OF MARKET

$1.8billion

US Market 2015

$3.1billion

Worldwide marker 2015 (CAGR 7%)

CLINICAL NEED

81,000 to 211,000

PICC-Related DVT Incidents in US per year* 

$12,000

Estimated cost per incident **

$1billion to $2.5billion

PICC-related DVT cost in US per year 

* Millennium Research, Evans et al 2010, Cowl et al, 2000; ** Lissovoy et al 2000;
Body Diagram

IBI SOLUTION

Signed deal with Angiodynamics to market Bioflow PICC

Average reduction across 8500 BioFlo PICCs studied

Numbers

Size of dialysis market

SIZE OF MARKET

Dialysis is the largest blood contacting medical device market with 2.7 million patients worldwide. By the year 2020, the global dialysis market is estimated to reach $100 billion.

CLINICAL NEED

ESRD (end stage renal disease) cost to US Medicare (2013) $30 billion (7% of US Medicare budget). Thrombus formation has significant negative impact on:

  • Dialyzers: poor clearance, increased need for anticoagulants, platelet and blood loss
  • Extracorporeal tubing: clotting, potential downstream emboli

IBI SOLUTION

In the bovine blood loop model, Endexo enhanced dialyzers showed both a significant (80%) decrease in header pressure (a surrogate for filter failure) as well as a 60% reduction in platelet adherence vs. control.

Endexo Dialyzers

DIALYSIS

DRUG ELUTING BALLOONS

SIZE OF MARKET

The worldwide Drug Eluting Balloon market is estimated to be $1B in 2020.*

CLINICAL NEED

A number of drug coated balloons which are currently on the market lack coating consistency, suffer from significant loss in transit and generate significant particulates. This can result in a lack of uniform drug release and potentially poor clinical outcomes.

arterial stenosis

IBI SOLUTION

The IBI DCB solution has a consistent and uniform coating with minimal particulates, low loss in transit and competitive tissue uptake.

*(Source: Medtronic Corporate Presentation).

Arterial stenosis

Potential arterial stenosis sites

SIZE OF MARKET

The worldwide market for dental implants in 2016 was estimated at $5.7B.*

*(Straumann Capital Markets Day 2012 Investor Presentation)

DENTAL IMPLANTS

CLINICAL NEED

Infection is a significant issue for both de novo dental implants as well as historic implants where peri-implantitis affects over 10% of patients four years after the initial procedure.

The prevalence of peri-implantitis: How big is the problem?

IBI SOLUTION

IBI has developed a number of product prototypes whereby antimicrobial agents are delivered directly from the dental implant to combat infection risks in both de novo implants and revisions due to peri-implantitis.

Dental Implants

Powered by Innovasium